Skip to main content
An official website of the United States government
Grant Details

Grant Number: 5R01CA136591-05 Interpret this number
Primary Investigator: Jelinek, Diane
Organization: Mayo Clinic Rochester
Project Title: Role of the Bcr in B Cell Chronic Lymphocytic Leukemia
Fiscal Year: 2013


DESCRIPTION (provided by applicant): B cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia among older adults in Western countries and is a significant cause of morbidity and mortality in the older adult population. We believe the B cell receptor (BCR) plays a crucial role in dictating the behavior of the malignant clone in B-CLL and in turn dictates clinical behavior of B-CLL. Our data and that obtained by others provide compelling evidence that the use of specific immunoglobulin heavy chain variable region (IGHV) genes in CLL is non-random and the IGH complementarity determining region 3 (CDR3) is remarkably homologous in certain CLL patients. In addition, the somatic hypermutation (SHM) status of the IGHV gene in the leukemic cell BCR is now a validated and powerful prognostic factor. Regardless of SHM status, all CLL B cells more closely resemble antigen experienced memory rather than naive B cells and some CLL B cells display a molecular phenotype which is similar to BCR-stimulated normal B cells. These observations collectively support the hypothesis that antigenic stimulation influences the development and/or course of B-CLL. Several broad questions concerning the biological role of the BCR in this disease remain unanswered. First, does the BCR continue to play an ongoing role in the biology of B-CLL, and if so, is this uniformly displayed by all patient leukemic B cells? Two, do CLL B cells expressing stereotyped BCRs recognize similar antigens, and if so, does this feature permit insight into the etiology of this disease and can this information be used to devise timely novel therapeutic interventions? Third, what is the relationship between molecular features of the BCR and clinical outcome? We are uniquely positioned to answer these questions because of our exceptional access to primary CLL B cells and an extensive cell bank of over 3000 cryopreserved vials of high quality cells collected as a result of our ongoing efforts to determine the IGHV molecular features of B-CLL patients, now numbering over 1000 patients. In addition, these data are integrated into a clinical data base which features invaluable long term clinical outcome data on each patient as well as expression levels of other biologically relevant molecules with prognostic significance and cytogenetic (FISH) data characterizing the most common CLL-associated genetic abnormalities. Thus, to answer these questions and test our unifying hypothesis that the BCR is functional and plays a critical role in the biology of malignant B cells in B-CLL and clinical outcome of this disease, we propose a comprehensive experimental strategy that will: i) systematically link BCR mediated signaling competencies with molecular BCR features that are critical for in vivo leukemic B cell survival, growth, and accumulation over time; ii) investigate BCR antigen recognition and identify shared epitopes recognized by CLL B cells expressing canonical receptors; and iii) probe the relevance of the BCR to the leukemic B cell process in CLL by correlating various IGHV molecular features with patient clinical outcome and other prognostic factors via our access to an invaluable clinical and research database.


Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.
Authors: Baliakas P. , Agathangelidis A. , Hadzidimitriou A. , Sutton L.A. , Minga E. , Tsanousa A. , Scarfò L. , Davis Z. , Yan X.J. , Shanafelt T. , et al. .
Source: Blood, 2015-01-29; 125(5), p. 856-9.
EPub date: 2014-12-17.
PMID: 25634617
Related Citations

Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.
Authors: Laurie C.C. , Laurie C.A. , Smoley S.A. , Carlson E.E. , Flinn I. , Fridley B.L. , Greisman H.A. , Gribben J.G. , Jelinek D.F. , Nelson S.C. , et al. .
Source: Cancer genetics, 2014 Jan-Feb; 207(1-2), p. 19-30.
EPub date: 2014-01-17.
PMID: 24613276
Related Citations

Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells.
Authors: Wu X. , Tschumper R.C. , Jelinek D.F. .
Source: Leukemia, 2013 Nov; 27(11), p. 2264-7.
EPub date: 2013-05-20.
PMID: 23685408
Related Citations

The histone methyltransferase MMSET regulates class switch recombination.
Authors: Pei H. , Wu X. , Liu T. , Yu K. , Jelinek D.F. , Lou Z. .
Source: Journal of immunology (Baltimore, Md. : 1950), 2013-01-15; 190(2), p. 756-63.
EPub date: 2012-12-14.
PMID: 23241889
Related Citations

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.
Authors: Braggio E. , Kay N.E. , VanWier S. , Tschumper R.C. , Smoley S. , Eckel-Passow J.E. , Sassoon T. , Barrett M. , Van Dyke D.L. , Byrd J.C. , et al. .
Source: Leukemia, 2012 Jul; 26(7), p. 1698-701.
EPub date: 2012-01-20.
PMID: 22261920
Related Citations

Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells.
Authors: Wu X. , Smoley S.A. , Peterson M.A. , Walters D.K. , Arendt B.K. , Nowakowski G.S. , Van Dyke D.L. , Kay N.E. , Jelinek D.F. .
Source: British journal of haematology, 2011 May; 153(3), p. 402-5.
EPub date: 2011-02-17.
PMID: 21323871
Related Citations

Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression.
Authors: Gutierrez A. , Arendt B.K. , Tschumper R.C. , Kay N.E. , Zent C.S. , Jelinek D.F. .
Source: PloS one, 2011; 6(10), p. e26056.
EPub date: 2011-10-06.
PMID: 21998751
Related Citations

Selective induction of DNA repair pathways in human B cells activated by CD4+ T cells.
Authors: Wu X. , Tschumper R.C. , Gutierrez A. , Mihalcik S.A. , Nowakowski G.S. , Jelinek D.F. .
Source: PloS one, 2010-12-16; 5(12), p. e15549.
EPub date: 2010-12-16.
PMID: 21179576
Related Citations

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.
Authors: Kay N.E. , Eckel-Passow J.E. , Braggio E. , Vanwier S. , Shanafelt T.D. , Van Dyke D.L. , Jelinek D.F. , Tschumper R.C. , Kipps T. , Byrd J.C. , et al. .
Source: Cancer genetics and cytogenetics, 2010 Dec; 203(2), p. 161-8.
PMID: 21156228
Related Citations

Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.
Authors: Ding W. , Knox T.R. , Tschumper R.C. , Wu W. , Schwager S.M. , Boysen J.C. , Jelinek D.F. , Kay N.E. .
Source: Blood, 2010-10-21; 116(16), p. 2984-93.
EPub date: 2010-07-06.
PMID: 20606160
Related Citations

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.
Authors: Gutierrez A. , Tschumper R.C. , Wu X. , Shanafelt T.D. , Eckel-Passow J. , Huddleston P.M. , Slager S.L. , Kay N.E. , Jelinek D.F. .
Source: Blood, 2010-10-21; 116(16), p. 2975-83.
EPub date: 2010-07-01.
PMID: 20595513
Related Citations

Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.
Authors: Shanafelt T.D. , Rabe K.G. , Kay N.E. , Zent C.S. , Jelinek D.F. , Reinalda M.S. , Schwager S.M. , Bowen D.A. , Slager S.L. , Hanson C.A. , et al. .
Source: Cancer, 2010-10-15; 116(20), p. 4777-87.
PMID: 20578179
Related Citations

Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
Authors: Kay N.E. , Wu W. , Kabat B. , LaPlant B. , Lin T.S. , Byrd J.C. , Jelinek D.F. , Grever M.R. , Zent C.S. , Call T.G. , et al. .
Source: Cancer, 2010-05-01; 116(9), p. 2180-7.
PMID: 20187101
Related Citations

Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.
Authors: Shanafelt T.D. , Kay N.E. , Rabe K.G. , Call T.G. , Zent C.S. , Maddocks K. , Jenkins G. , Jelinek D.F. , Morice W.G. , Boysen J. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-08-20; 27(24), p. 3959-63.
EPub date: 2009-07-20.
PMID: 19620484
Related Citations

Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
Authors: Shanafelt T.D. , Call T.G. , Zent C.S. , LaPlant B. , Bowen D.A. , Roos M. , Secreto C.R. , Ghosh A.K. , Kabat B.F. , Lee M.J. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-08-10; 27(23), p. 3808-14.
EPub date: 2009-05-26.
PMID: 19470922
Related Citations

B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.
Authors: Shanafelt T.D. , Kay N.E. , Jenkins G. , Call T.G. , Zent C.S. , Jelinek D.F. , Morice W.G. , Boysen J. , Zakko L. , Schwager S. , et al. .
Source: Blood, 2009-04-30; 113(18), p. 4188-96.
EPub date: 2008-11-17.
PMID: 19015397
Related Citations

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.
Authors: Nowakowski G.S. , Hoyer J.D. , Shanafelt T.D. , Zent C.S. , Call T.G. , Bone N.D. , Laplant B. , Dewald G.W. , Tschumper R.C. , Jelinek D.F. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-10; 27(11), p. 1844-9.
EPub date: 2009-03-02.
PMID: 19255329
Related Citations

Back to Top